stockrowRepligen Corporation
RGEN Healthcare Medical Instruments & Supplies
Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024.
- Revenue
- +10.9%
- EPS
- −351.9%
- Free cash flow
- −11.5%
- Total debt
- +3.28%
Quarter to September 2026, against a year earlier
Follow RGEN
Alert me
Repligen Corporation (RGEN) Net income
Repligen Corporation's net income for fiscal 2025 was $48.9M, compared with −$25.5M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$11.8M. Over the past ten years it has ranged from −$25.5M (fiscal 2024) to $186.0M (fiscal 2022); the current reading is higher than 73% of that period. Repligen Corporation ranks 37th of 51 Medical Instruments & Supplies companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $48.9M | — |
| FY2024 | −$25.5M | — |
| FY2023 | $35.6M | (80.86%) |
| FY2022 | $186.0M | 44.95% |
| FY2021 | $128.3M | 114.08% |
| FY2020 | $59.9M | 179.88% |
| FY2019 | $21.4M | 28.85% |
| FY2018 | $16.6M | (41.39%) |
| FY2017 | $28.4M | 142.73% |
| FY2016 | $11.7M | 25.00% |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | −$38.4M | — |
| Jun 2026 | $5.0M | (39.90%) |
| Mar 2026 | $8.3M | (37.28%) |
| Dec 2025 | $13.3M | (10.89%) |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| COO The Cooper Companies, Inc. compare | $570.3M |
| ALGN Align Technology, Inc. compare | $413.6M |
| AVTR Avantor, Inc. compare | $337.2M |
| ATR AptarGroup, Inc. compare | $267.9M |
| SOLV Solventum Corporation compare | $156.0M |
| RGEN Repligen Corporation | −$11.8M |
| BLCO Bausch + Lomb Corporation compare | −$103.0M |
| BAX Baxter International Inc. compare | −$723.0M |
| TFX Teleflex Incorporated compare | −$1.0B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on RGEN
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement